NIH/NIAID

Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)

Grant Source: 
NIH/NIAID

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate development of safe and effective long-acting drug delivery systems (LA-DDS) for improved, simplified treatment of HIV-1 in children. This FOA invites applicants engaged in the development of existing LA-DDS platforms at early product development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-1 infected children. Collaborative research partnerships with industry are required.

Application Deadline: March 13, 2019 - 5:00 PM local time of applicant

Health Topics: 
HIV
Pediatric Formulations

    Development of Ultra Long-Acting Oral HIV Therapies

    Grant Source: 
    NIH/NIAID

    Non-adherence to anti-retroviral therapy by HIV+ patients results in increased viral loads and risk of emergence of drug-resistant HIV strains. This poses a major public health threat. Lyndra Co. has developed an orally available, long-acting drug delivery system that it will now formulate to deliver anti-retrovirals.

    Health Topics: 
    HIV
    LA/ER Oral Therapy

      Pages